Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Next Previous
X
Search
Trial Profile

An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buparlisib (Primary) ; Cetuximab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Sep 2020 Results assessing efficacy of a combination of buparlisib and cetuximab on the patient-derived xenografts models published in the British Journal of Cancer
    • 05 Apr 2017 Status changed from recruiting to completed, based on the results presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top